Ticagrelor
| Status | Pipeline |
| Development phase | |
| Therapeutic cat. | Blood Forming |
| Polymorphic form | Form II |
| CAS No. | 274693-27-5 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Ticagrelor is a P2Y12 platelet inhibitor prescribed for patients with a history of myocardial infarction or acute coronary syndrome (ACS) to prevent future heart attacks, strokes, and cardiovascular death.
Ticagrelor is prescribed to lower the risk of cardiovascular death, heart attack, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It is also used to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.
Polpharma API
- Free of nitrosamines risk
- Own process patent
- Ability to obtain pure and stable form II
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulationare met.
